Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC)A GOG Foundation study

GOG 244, the lymphedema and gynecologic cancer (LEG) studyIncidence and risk factors in newly diagnosed patients

The FILM TrialA randomized phase III multicenter study assessing near infrared fluorescence in the identification of sentinel lymph nodes (SLN)

Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial

Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002)

Predictive biomarkers of endometrial cancer responseResults from NRG Oncology/Gynecologic Oncology Group study 86P

Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer

Phase II, two-stage study of avelumab in patientswith microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer

GOG 244, The lymphedema and gynecologic cancer (LEG) studyThe association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lower extremity lymphedema

Preliminary data on the use of combination carboplatin, paclitaxel and pembrolizumab therapy for ovarian cancer

Novel immunooncology agent, small-molecule ror agonist lyc-55716Tumor selection process for phase IIa expansion and rationale for clinical evaluation in ovarian cancer following phase I dose finding

A phase II trial of TPIV200 (a polypeptide vaccine against folate receptor alpha) plus durvalumab (anti-PD-L1 antibody) in patients with platinum-resistant ovarian cancer

Factors associated with completion and physician and patient attitudes towards salpingectomy at the time of cesarean delivery

Phase IB dose escalation and expansion trial of the oral hedgehog inhibitor sonidegib (LDE225) and weekly paclitaxel in platinum-resistant ovarian cancer (NCT02195973)